4.2 Abstract in Atti di convegno

4.2 Abstract in Atti di convegno: [990] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 321 a 340 di 990

A dose dense schedule improves antitumor activity of trabectedin in myxoid liposarcoma with type III FUS-CHOP chimera

2014-01-01 Uboldi, S; Frapolli, R; Bello, E; Brich, S; Bozzi, F; Sanfilippo, R; Casali, Pg; Gronchi, A; Galmarini, Cm; Sousa-Faro, Jmf; Pilotti, S; D'Incalci, M

MIRNA181A-5P EXPRESSION AS A BIOMARKER OF TGFB PATHWAY ACTIVATION ASSOCIATED WITH ONCOLOGIC OUTCOME AND TUMOR DIFFUSION IN HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER

2017-01-01 Ceppi, L; Palazzi, S; Romualdi, C; Dilorenzo, P; Grassi, T; Biagioli, E; Paracchini, L; Milani, R; Buda, A; D'Incalci, M; Marchini, S; Fruscio, R

In silico rendering of cell cycle progression of erlotinib and gemcitabine treatment in pancreatic cancer cells

2015-01-01 Lupi, M; Falcetta, F; D'Incalci, M; Ubezio, P

Pharmacokinetic study of trabectedin administered as 24-hour infusion in elderly patients with advanced soft tissue sarcoma (STS) treated according to the TR1US ISG study

2016-01-01 Ferrari, M; Grosso, F; Grignani, G; Ibrahim, T; Tamberi, S; Marra, D; Marchesi, E; Porcu, L; D'Incalci, M; Zucchetti, M

MIRNA LANDSCAPE IN STAGE I EPITHELIAL OVARIAN CANCER DEFINES THE HISTOTYPE SPECIFICITIES

2013-01-01 Bignotti, E; Calura, E; Fruscio, R; Paracchini, L; Ravaggi, A; Zanotti, L; Tognon, G; D'Incalci, M; Sartori, E; Pecorelli, S

MICRORNA PROFILE IN BONE MARROW FIBROBLASTS FROM PATIENTS WITH MULTIPLE MYELOMA

2015-01-01 Desantis, V; Caparrotta, I; Beltrame, L; Di Marzo, L; Marchini, S; Catacchio, I; D'Incalci, M; Vacca, A; Frassanito, Ma

DIAGNOSTIC AND PROGNOSTIC IMPACT OF MICRORNA EXPRESSION IN SERUM OF HIGH-GRADE SEROUS OVARIAN CARCINOMA PATIENTS

2015-01-01 Bignotti, E; Todeschini, P; Ravaggi, A; Ferracin, M; Sartori, E; Odicino, F; Tognon, G; Negrini, M; D'Incalci, M; Marchini, S; Romualdi, C

Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial

2012-01-01 Zangarini, M; Sala, F; Camboni, Mg; Cereda, R; Livi, V; Bahleda, R; Dienstmann, R; Delmonte, A; D'Incalci, M; Zucchetti, M

OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents

2015-01-01 Vazquez, R; Astorgues-Xerri, L; Riveiro, Me; Beltrame, L; Marchini, S; Bertoni, F; Kwee, I; Mohamed, M; Cvitkovic, E; Frapolli, R; D'Incalci, M

CIRCULATING MIRNA LANDSCAPE IDENTIFIES MIR-1246 AS PROMISING DIAGNOSTIC BIOMARKER IN HIGH-GRADE SEROUS OVARIAN CARCINOMA: A VALIDATION ACROSS TWO INDEPENDENT COHORTS

2017-01-01 Bignotti, E; Todeschini, P; Salviato, E; Paracchini, L; Ferracin, M; Petrillo, M; Zanotti, L; Tognon, G; Gambino, A; Calura, E; Beltrame, L; Odicino, F; Sartori, E; Scambia, G; Negrini, M; Ravaggi, A; D'Incalci, M; Marchini, S; Romualdi, C

Activation of TGF-Beta Pathway Through Mir-181a and Psmad-2 Overexpression Drives Resistance To Neoadjuvant Chemotherapy in High Grade Serous Advanced Ovarian Cancer

2015-01-01 Petrillo, M; Marchini, S; Romualdi, C; Beltrame, L; Martinelli, E; Difeo, A; D'Incalci, M; Zannoni, Gf; Scambia, G

Insulin-like growth factor binding protein-4 (IGFBP-4) tumor and serum levels are increased across all stages of epithelial ovarian cancer

2012-01-01 Mosig, R; Lobl, M; Cohen, S; Chudin, E; Fruscio, R; Marchini, S; D'Incalci, M; Sachidanandam, R; Dottino, P; Martignetti, J

OTX015, a novel pan BET-BRD inhibitor is active in non-small-cell lung cancer (NSCLC) cell lines bearing the fusion protein EML4-ALK

2014-01-01 Vazquez, R; Astorgues-Xerri, L; Bekradda, M; Cvitkovic, E; Herait, P; Boi, M; Inghirami, G; D'Incalci, M; Riveiro, Me; Raymond, E

PM01183 shows an improved therapeutic index relative to trabectedin and suppresses EWS/FLI1 activity at clinically achievable concentrations

2014-01-01 Harlow, M; Maloney, N; Navarro, Mjg; D'Incalci, M; Galmarini, C; Marin, Pma; Grohar, P

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas

2015-01-01 Herzog, J; Klot-Heydenfeldt, F; Rossig, C; Dirksen, U; van den Brande, J; D'Incalci, M; Grohar, P; von Luettichau, I; Berdel, W; Burdach, S

MicroRNA Expression Profiling of Stage I Ovarian Carcinoma Reveals Signatures Characterizing the Different Tumor Grades and Histotypes

2012-01-01 Bignotti, E; Calura, E; Nerini, If; Dell'Orto, F; Romualdi, C; Fruscio, R; Ravaggi, A; Tognon, G; D'Incalci, M; Pecorelli, S

The Biological Connection Markup Language - a Data Format to Visualize, Annotate and Analyze Biological Pathways

2012-01-01 Beltrame, L; Calura, E; Popovici, R; Draghici, S; Cavalieri, D; D'Incalci, M

Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study

2014-01-01 Boddy, Av; Andre, N; Bisogno, G; Boos, J; D'Incalci, M; Kontny, N; Krischke, M; Voeller, S; Hempel, G

INITIAL RESULTS OF CONCORDANCE BETWEEN THE BIOFIELD DIAGNOSTIC SYSTEM (BDS ) AND KI-67 LABELLING INDEX TO DISCRIMINATE HIGHLY PROLIFERATING PALPABLE BREAST LESIONS

2002-01-01 Tinterri, C

PLASMA D-DIMER LEVEL IN OPERABLE BREAST CANCER AND CORRELATION WITH LYMPH NODES INVOLVEMENT

2002-01-01 Tinterri, C

Titolo	Data di pubblicazione	Autore(i)
A dose dense schedule improves antitumor activity of trabectedin in myxoid liposarcoma with type III FUS-CHOP chimera	1-gen-2014	Uboldi, S; Frapolli, R; Bello, E; Brich, S; Bozzi, F; Sanfilippo, R; Casali, Pg; Gronchi, A; Galmarini, Cm; Sousa-Faro, Jmf; Pilotti, S; D'Incalci, M
MIRNA181A-5P EXPRESSION AS A BIOMARKER OF TGFB PATHWAY ACTIVATION ASSOCIATED WITH ONCOLOGIC OUTCOME AND TUMOR DIFFUSION IN HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER	1-gen-2017	Ceppi, L; Palazzi, S; Romualdi, C; Dilorenzo, P; Grassi, T; Biagioli, E; Paracchini, L; Milani, R; Buda, A; D'Incalci, M; Marchini, S; Fruscio, R
In silico rendering of cell cycle progression of erlotinib and gemcitabine treatment in pancreatic cancer cells	1-gen-2015	Lupi, M; Falcetta, F; D'Incalci, M; Ubezio, P
Pharmacokinetic study of trabectedin administered as 24-hour infusion in elderly patients with advanced soft tissue sarcoma (STS) treated according to the TR1US ISG study	1-gen-2016	Ferrari, M; Grosso, F; Grignani, G; Ibrahim, T; Tamberi, S; Marra, D; Marchesi, E; Porcu, L; D'Incalci, M; Zucchetti, M
MIRNA LANDSCAPE IN STAGE I EPITHELIAL OVARIAN CANCER DEFINES THE HISTOTYPE SPECIFICITIES	1-gen-2013	Bignotti, E; Calura, E; Fruscio, R; Paracchini, L; Ravaggi, A; Zanotti, L; Tognon, G; D'Incalci, M; Sartori, E; Pecorelli, S
MICRORNA PROFILE IN BONE MARROW FIBROBLASTS FROM PATIENTS WITH MULTIPLE MYELOMA	1-gen-2015	Desantis, V; Caparrotta, I; Beltrame, L; Di Marzo, L; Marchini, S; Catacchio, I; D'Incalci, M; Vacca, A; Frassanito, Ma
DIAGNOSTIC AND PROGNOSTIC IMPACT OF MICRORNA EXPRESSION IN SERUM OF HIGH-GRADE SEROUS OVARIAN CARCINOMA PATIENTS	1-gen-2015	Bignotti, E; Todeschini, P; Ravaggi, A; Ferracin, M; Sartori, E; Odicino, F; Tognon, G; Negrini, M; D'Incalci, M; Marchini, S; Romualdi, C
Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial	1-gen-2012	Zangarini, M; Sala, F; Camboni, Mg; Cereda, R; Livi, V; Bahleda, R; Dienstmann, R; Delmonte, A; D'Incalci, M; Zucchetti, M
OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents	1-gen-2015	Vazquez, R; Astorgues-Xerri, L; Riveiro, Me; Beltrame, L; Marchini, S; Bertoni, F; Kwee, I; Mohamed, M; Cvitkovic, E; Frapolli, R; D'Incalci, M
CIRCULATING MIRNA LANDSCAPE IDENTIFIES MIR-1246 AS PROMISING DIAGNOSTIC BIOMARKER IN HIGH-GRADE SEROUS OVARIAN CARCINOMA: A VALIDATION ACROSS TWO INDEPENDENT COHORTS	1-gen-2017	Bignotti, E; Todeschini, P; Salviato, E; Paracchini, L; Ferracin, M; Petrillo, M; Zanotti, L; Tognon, G; Gambino, A; Calura, E; Beltrame, L; Odicino, F; Sartori, E; Scambia, G; Negrini, M; Ravaggi, A; D'Incalci, M; Marchini, S; Romualdi, C
Activation of TGF-Beta Pathway Through Mir-181a and Psmad-2 Overexpression Drives Resistance To Neoadjuvant Chemotherapy in High Grade Serous Advanced Ovarian Cancer	1-gen-2015	Petrillo, M; Marchini, S; Romualdi, C; Beltrame, L; Martinelli, E; Difeo, A; D'Incalci, M; Zannoni, Gf; Scambia, G
Insulin-like growth factor binding protein-4 (IGFBP-4) tumor and serum levels are increased across all stages of epithelial ovarian cancer	1-gen-2012	Mosig, R; Lobl, M; Cohen, S; Chudin, E; Fruscio, R; Marchini, S; D'Incalci, M; Sachidanandam, R; Dottino, P; Martignetti, J
OTX015, a novel pan BET-BRD inhibitor is active in non-small-cell lung cancer (NSCLC) cell lines bearing the fusion protein EML4-ALK	1-gen-2014	Vazquez, R; Astorgues-Xerri, L; Bekradda, M; Cvitkovic, E; Herait, P; Boi, M; Inghirami, G; D'Incalci, M; Riveiro, Me; Raymond, E
PM01183 shows an improved therapeutic index relative to trabectedin and suppresses EWS/FLI1 activity at clinically achievable concentrations	1-gen-2014	Harlow, M; Maloney, N; Navarro, Mjg; D'Incalci, M; Galmarini, C; Marin, Pma; Grohar, P
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas	1-gen-2015	Herzog, J; Klot-Heydenfeldt, F; Rossig, C; Dirksen, U; van den Brande, J; D'Incalci, M; Grohar, P; von Luettichau, I; Berdel, W; Burdach, S
MicroRNA Expression Profiling of Stage I Ovarian Carcinoma Reveals Signatures Characterizing the Different Tumor Grades and Histotypes	1-gen-2012	Bignotti, E; Calura, E; Nerini, If; Dell'Orto, F; Romualdi, C; Fruscio, R; Ravaggi, A; Tognon, G; D'Incalci, M; Pecorelli, S
The Biological Connection Markup Language - a Data Format to Visualize, Annotate and Analyze Biological Pathways	1-gen-2012	Beltrame, L; Calura, E; Popovici, R; Draghici, S; Cavalieri, D; D'Incalci, M
Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study	1-gen-2014	Boddy, Av; Andre, N; Bisogno, G; Boos, J; D'Incalci, M; Kontny, N; Krischke, M; Voeller, S; Hempel, G
INITIAL RESULTS OF CONCORDANCE BETWEEN THE BIOFIELD DIAGNOSTIC SYSTEM (BDS ) AND KI-67 LABELLING INDEX TO DISCRIMINATE HIGHLY PROLIFERATING PALPABLE BREAST LESIONS	1-gen-2002	Tinterri, C
PLASMA D-DIMER LEVEL IN OPERABLE BREAST CANCER AND CORRELATION WITH LYMPH NODES INVOLVEMENT	1-gen-2002	Tinterri, C

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 321 a 340 di 990

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext963
reserved27